Recent IPO Clovis Oncology (CLVS -9.8%) takes a hit after posting a $14.9M Q4 loss, despite showing improvement over the prior year period. Bottom line margins were hit as R&D expenses nearly doubled due to the expanded development activities for its CO-101 and CO-1686 drugs, as well as the in-licensing of Rucaparib from Pfizer in mid 2011.
Check out Seeking Alpha’s new Earnings Center
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Nov 19, 2014)
at Nasdaq.com (Nov 17, 2014)
at CNBC.com (Sep 29, 2014)
at CNBC.com (Jun 3, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs